Is ResMed (RMD) a risky stock?
As of July 21, 2026, Clavix grades ResMed (RMD) C+ for risk, a composite score of 61 out of 100 on an A+ to F scale, which puts RMD in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind RMD's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how RMD scores on each, as of July 21, 2026.
What's moving RMD's risk right now
Company-specific signals Clavix flags behind RMD's current grade, drawn from recent news and filings as of July 21, 2026.
Guidance cuts or consensus estimate reductions signal near-term earnings pressure that typically precedes multiple contraction.
The current multiple prices in near-perfect execution; any earnings miss or guidance cut would cause outsized multiple compression.
This safety issue could lead to a recall, regulatory scrutiny, potential litigation costs, and reputational damage for ResMed's ventilator segment, though the Astral line represen…
What a C+ grade means
On the Clavix A+ to F scale, RMD's composite of 61 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell RMD or any security. Grades are risk indicators, not predictions of return. Data may be delayed.